Composition : Trimetazidine Dihydrochloride 20mg & Modified release 35mg Tablet.
Indication : This tablet is indicated for the treatment of Ischaemic heart disease (angina pectoris, sequelae of infarction), adjuvant symptomatic treatment of vertigo and tinnitus, adjuvant treatment of the decline visual acuity and visual field disturbances, presumably of vascular origin.
Dosage and administration : Trimet One tablet (20mg) thrice daily after meals. Trimet-MR one tablet twice daily at mealtimes in the morning and evening. Or as directed by the registered physician.
Use in pregnancy and lactation : No drug interactions have so far been reported. In particular, no interactions of Trimetazidine with betablockers, calcium antagonists, nitrates, heparin, hypolipidemic agents or digitalis have been reported.